Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy
Caitlin D. Lowery(Eli Lilly (United States)), Beverly L. Falcón(Eli Lilly (United States))
Cited by 18
Related Papers
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
|New England Journal of Medicine|2025|411